Skip to main content

Table 14 Medius Associates’ royalty rate by development stage (Source: www.medius-associate.com) (IPRA Inc 2012)

From: Valuations using royalty data in the life sciences area—focused on anticancer and cardiovascular therapies

Development stage

Royalty rate

Pre-clinical

0–5 %

Phase I

5–10 %

Phase II

8–15 %

Phase III

10–20 %

Launched product

20 % +